In December 2024, thanks to collaboration with researchers at the University of South Carolina, Bina Therapeutics achieved a significant milestone by establishing a master cell bank for our Pseudomyxoma Peritonei (PMP) research.
As we begin 2025, we are pleased to share the continued progress by successfully culturing a series of PMP cell lines from our master bank. These cell lines exhibit the defining features of PMP cells, providing a foundation to advance our preclinical work for TRAABA24 in organotypic models.
Methods
LAMN PMP cells were cultured with Gibco OptiMEM, a chemically defined minimal essential growth media (MEM). This improved MEM enables reduced fetal bovine serum concentrations with no change in growth rate or morphology, ideal for novel 3D co-culture models and TRAABA24 formulation development. Below are a few microscopic images of the cell lines captured at various magnification levels, exhibiting morphology and growth characteristics typical for PMP:
40x Magnification: Rapidly proliferating PMP cell culture at 40x magnification, which quickly reached confluence following cryorecovery.
100x Magnification: Detailed view of PMP cell structures at 100x magnification, demonstrating characteristic ‘cobblestone’ cell morphology.
200x Magnification: Individual PMP cells clearly visible at 200x magnification, showing dividing cells and highly active nucleoli. Excessive production of mucin is a pathogenic hallmark of PMP and mucin-containing vacuoles are already visible early in culture, representing a formidable barrier to treatment of mature PMP cancers.
These advances support bringing our research closer to delivering targeted and more effective therapies for patients living with this challenging disease. Remember, you can stay updated on our progress by tracking our activity, subscribing to our newsletter, or visiting the News and Updates section on our website.
